-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gorillace Pharmaceutical Limited (HKEx: 1672, "Graeley") announced the completion
The study (clinical trial registration number: NCT05129189) aimed to evaluate the efficacy
The experimental regimen was 1 mg/kg ASC22 (envorizumab) every 4 weeks in combination with 10 mg cedabenamide tablets twice weekly for 12 weeks
ASC22 (envorizumab) is a subcutaneously injected PD-L1 single-domain antibody that has the potential
"The clinical study of ASC22 (envorizumab) and cedabenamide for functional cure of human immunodeficiency virus (HIV) infection completed the first patient enrollment on July 1 this year, and I am very pleased that this study completed the enrollment of all patients in less than 3 months
Although standard antiretroviral therapy is becoming widespread and improving, functional cures for people living with HIV remain a challenge in China and around the
Dr.